Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel - PubMed
3 hours ago
- #immunotherapy
- #TTFields
- #pancreatic cancer
- Tumor Treating Fields (TTFields) are an approved therapy for glioblastoma, pleural mesothelioma, and non-small cell lung cancer.
- A phase 3 trial showed TTFields with gemcitabine/nab-paclitaxel (Gem/NabP) increased survival in pancreatic adenocarcinoma.
- TTFields suppressed c-Myc expression and induced immunogenic cell death (ICD) in pancreatic cancer models.
- Combining TTFields with Gem/NabP enhanced these effects, though causality between c-Myc and immune responses wasn't established.
- In vivo, TTFields activated dendritic cells, increased effector memory T cells, and improved tumor leukocyte infiltration.
- TTFields with Gem/NabP reduced tumor volume, decreased M-MDSCs, and increased the lymphocyte-to-monocyte ratio (LMR).
- TTFields may enhance therapeutic efficacy and enable combination with immunotherapies.
- A phase 2 trial is investigating TTFields with Gem/NabP and immune checkpoint inhibitors for metastatic PDAC.